Evidence map›Paper›PMID 42075264›Full record

ArticleMicroorganisms2026

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

Yusuke Tanaka, Daiki Miki, C Nelson Hayes, Michihiko Kawahara, Saki Sueda, Tomoaki Emori, Kou Hashimoto, Yuri Mitamura, Aiko Tanaka, Keiichi Hiraoka and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yusuke TanakaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Daiki MikiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0002-6505-9826
C Nelson HayesDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0003-1691-3544
Michihiko KawaharaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Saki SuedaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Tomoaki EmoriDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Kou HashimotoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0009-0001-1635-7763
Yuri MitamuraDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Aiko TanakaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Keiichi HiraokaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Yusuke JohiraDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Ryoichi MiuraDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Hatsue FujinoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0002-9691-4960
Atsushi OnoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0002-2482-945X
Eisuke MurakamiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0003-0357-2795
Tomokazu KawaokaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Masataka TsugeDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0001-7591-8287
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.

Funding

Japan Society for the Promotion of Science JP23K07416, JP20K08288JSPS Program for Forming Japan's Peak Research Universities (J-PEAKS) JPJS00420230011
6 · The paper itself

Abstract

Recent findings suggest that the gut microbiota modulates antitumor immunity and influences the efficacy of immune checkpoint inhibitors, yet no established consensus has been reached. This study examined the association between gut microbiota composition before initiation of atezolizumab plus bevacizumab combination therapy (Atez/Bev) and treatment response in patients with advanced hepatocellular carcinoma (HCC). Twenty-nine patients with advanced HCC from whom stool samples were collected before Atez/Bev treatment were enrolled. A comparative analysis was performed between the responder and non-responder groups to identify the genera associated with treatment response and progression-free survival (PFS). A total of 90 genera were identified. ROC analysis was performed for the responder and non-responder groups using the relative abundance of each genus. The prevalence of

Indexed as

atezolizumab plus bevacizumab combination therapygut microbiota: immune checkpoint inhibitorhepatocellular carcinomaprogression-free survivaltreatment response

Identifiers

PMID42075264
PMCPMC13119078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.